February 3, 2022
The MMA’s next noon-time forum will examine sodium-glucose cotransporter-2 (SGLT2) inhibitors, a new 'triple play' for diabetes, cardiovascular and kidney diseases. The forum will take place February 9 from noon to 1 p.m.
This forum will review the pharmacology of SGLT2 inhibitors and then discuss the role these drugs play in the management of type 2 diabetes. The evidence for improving cardiorenal outcomes will be presented and recommendations made for the use of these drugs in patients with cardiovascular or renal diseases. The session will conclude with a Q&A panel discussion.
The forum will be moderated by Andrew Olson, MD, and include Anne Bantle, MD, Prabhjot S. Nijjar, MD, and Mark Rosenberg, MD. All faculty for this forum are with the University of Minnesota Medical School.
Learning objectives for the forum include:
Describe the pharmacology of SGLT2 inhibitors and the use of these drugs in the management of type 2 diabetes mellitus.
Appraise the data supporting the cardiorenal protective effects of SGLT2 inhibitors.
Utilize SGLT2 inhibitors in the management of patients with diabetes, cardiovascular or kidney diseases.
To register, click here.
The forum is free to members, $15 for non-members. This forum is being held in partnership with the University of Minnesota.
August 20, 2026
A physician and Olympian will give an inspirational address as part of this year's Empowering Physicians event on Friday, September 25, at the Minneapolis Institute of Art.
August 20, 2026
Minnesota received some disturbing news this week from the Centers for Disease Control and Prevention (CDC), as data shows that for the 2025-2026 school year, vaccination rates decreased and non-medical exemptions increased.
August 20, 2026
On August 11, a federal appellate court sided with the Texas Medical Association (TMA) argument that the way the No Surprises Act’s qualifying payment amount (QPA) is calculated has historically favored payers in arbitration.